Which treatments for non-small cell lung cancer (NSCLC) are targeting KRAS mutations?

Updated: Aug 21, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Keith K Vaux, MD  more...
  • Print


No prospective trials have been conducted to demonstrate the potential value of testing for KRAS mutations and to tailor therapy accordingly.

Although meta-analyses indicate that patients with KRAS mutations have a lowered response to EGFR-TKIs, most of the trials evaluated were small and it is unclear whether mutation status predicts reduced progression-free or overall survival. [30] Subgroup analysis of data from clinical trials evaluating EGFR-TKIs and cetuximab also showed no independent association between KRAS mutation status and survival. [31, 32]

Nevertheless, despite the lack of definitive data demonstrating the benefit of KRAS mutation testing, the presence of mutations does seem to be associated with primary resistance to EGFR-TKI therapy. Testing can be considered to help in determining whether a patient might be a candidate for a TKI. [1]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!